Waszyrowski T, Kasprzak J D, Krzemińska-Pakuła M, Dziatkowiak A, Zasłonka J
Department of Cardiology and Cardiac Surgery, Medical University of Lódz, Poland.
Clin Cardiol. 1997 Oct;20(10):843-8. doi: 10.1002/clc.4960201010.
Aortic valve disease is an important and frequent clinical problem with a mortality rate as high as 50-80% in a 5-year natural history of patients with severe aortic valve disease. Biological or mechanical prosthesis implantation is the only way to improve prognosis.
The aim of our study was to assess the clinical outcome of aortic valve replacement according to the underlying valve pathology and the type of replacement device, that is, aortic homografts versus mechanical prostheses.
The study group consisted of 143 patients with a mean follow-up period of 4.1 +/- 2.7 years. All patients had annual clinical and Doppler echocardiographic evaluation.
Total 8-year mortality was 4.9% (7/143) including early mortality of 1.4%. Eight-year survival probability was not significantly higher in the homograft than in the mechanical prosthesis recipients. No differences were found among subgroups with aortic stenosis, insufficiency, and combined disease. Overall early and late complication rate (13.3 and 24.8%, respectively) was similar in homograft and mechanical valve recipients. The most common late complications were ventricular arrhythmia (10%) (Lown class I-III), predominantly in the homograft recipients (17.7 vs. 3.7%), and heart failure (9.2%), more frequent in mechanical valve recipients (14.8 vs. 1.6%). Thromboembolic events occurred in 6.3%, infective endocarditis in 4.2% (more common in mechanical valve recipients), serious bleeding in 3.7% (only in mechanical valve recipients). There was no significant difference in early and late complication rate among subgroups (aortic stenosis, insufficiency, and combined disease). Of the patients studied, 91.6% improved in functional status after surgery, with significantly better outcome in homograft recipients. The type of preexisting valve disease did not influence clinical improvement.
Early and late mortality as well as estimated probability of survival and hemodynamic improvement at 8-year follow-up after aortic valve replacement are independent of the type of implanted valve. Complication rate does not depend upon the type of preexisting valve pathology, but severe late complications are more common after mechanical valve implantation than after homograft implantation.
主动脉瓣疾病是一个重要且常见的临床问题,在重度主动脉瓣疾病患者的5年自然病程中,死亡率高达50 - 80%。生物或机械瓣膜置换是改善预后的唯一方法。
我们研究的目的是根据潜在的瓣膜病变和置换装置的类型,即主动脉同种异体移植物与机械瓣膜,评估主动脉瓣置换的临床结果。
研究组由143例患者组成,平均随访期为4.1±2.7年。所有患者每年进行临床和多普勒超声心动图评估。
8年总死亡率为4.9%(7/143),其中早期死亡率为1.4%。同种异体移植物受者的8年生存概率并不显著高于机械瓣膜受者。在主动脉狭窄、关闭不全和联合疾病的亚组之间未发现差异。同种异体移植物和机械瓣膜受者的总体早期和晚期并发症发生率(分别为13.3%和24.8%)相似。最常见的晚期并发症是室性心律失常(10%)(洛恩I - III级),主要发生在同种异体移植物受者中(17.7%对3.7%),以及心力衰竭(9.2%),在机械瓣膜受者中更常见(14.8%对1.6%)。血栓栓塞事件发生率为6.3%,感染性心内膜炎发生率为4.2%(在机械瓣膜受者中更常见),严重出血发生率为3.7%(仅在机械瓣膜受者中)。亚组(主动脉狭窄、关闭不全和联合疾病)之间的早期和晚期并发症发生率无显著差异。在研究的患者中,91.6%术后功能状态改善,同种异体移植物受者的结果明显更好。既往瓣膜疾病的类型不影响临床改善情况。
主动脉瓣置换术后8年随访的早期和晚期死亡率、估计生存概率和血流动力学改善情况与植入瓣膜的类型无关。并发症发生率不取决于既往瓣膜病变的类型,但机械瓣膜植入后严重晚期并发症比同种异体移植物植入后更常见。